Skip to content

Released Mar 12, 2020, after the close

10-K filed Mar 13, 2020, 73 days after period end · 0001390478-20-000007

Q4 2019 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$7.42MderivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$4,176,000N/M

What the release said

The release

Same quarter

MetricQ4 2019derived from reported figuresQ4 2018derived from reported figuresQ4 2017derived from reported figuresQ4 2016derived from reported figures
Net Income-$7.42M-$13.32M-$8.79M$352.00K

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR